Dec. 21 (UPI) --Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for treating moderate to severe obstructive sleep apnea.

The Food and Drug Administration on Friday approved Eli Lilly's blockbuster weight loss drug Zepbound for treating patients with the most common sleep-related breathing disorder, expanding its use ...

The Food and Drug Administration approved Zepbound as the first prescription medicine to treat sleep apnea on Friday—marking a significant win for the drug company Eli Lilly, which had Zepbound ...

The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity. Zepbound is the first medication approved ...

Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity. Zepbound is the first medication approved ...

In the trial that Lilly, the drug's manufacturer, submitted in April to the FDA, scientists reported that the drug helped people who were overweight or obese with sleep apnea reduce a standard ...

The New Holy Grail for Weight-Loss Drugs Is Sleep Apnea Popular anti-obesity medicines are in testing for a range of other diseases. Positive results could prompt more insurers to pay up.

FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S. The agency's decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain ...

The Food and Drug Administration on Friday approved Eli Lilly's blockbuster weight loss drug Zepbound for treating patients with the most common sleep-related breathing disorder, expanding its use ...